JPM26: ThermoFisher ‘very positive’ on strategic M&A as deals expand capabilities

ThermoFisher Scientific plans to drive share gain, pursue targeted mergers and acquisitions (M&A), and strengthen its end-to-end offering for pharmaceutical and biotechnology customers, CEO Marc N. Casper said at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. In a presentation at the conference, Casper said the company generated roughly $44bn in revenue in 2025. The company expects organic revenue growth in the range of 3% to 6% for the years 2026 and 2027. Following that period, it an ...